Cargando…
Evaluation of a multiplex ligation-dependent probe amplification assay for the detection of respiratory pathogens in oncological patients
BACKGROUND: Respiratory tract infections are widespread and may cause significant morbidity and mortality in immunosuppressed populations such as oncological patients. OBJECTIVES: The RealAccurate Respiratory RT PCR Kit covering 14 respiratory viruses was compared to the RespiFinder Smart22, a broad...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106480/ https://www.ncbi.nlm.nih.gov/pubmed/24684925 http://dx.doi.org/10.1016/j.jcv.2014.02.010 |
_version_ | 1783512614489292800 |
---|---|
author | Berning, Lucia Aberle, Stephan W. Simon, Benedikt Luger, Christoph Apfalter, Petra Machherndl-Spandl, Sigrid Kerschner, Heidrun |
author_facet | Berning, Lucia Aberle, Stephan W. Simon, Benedikt Luger, Christoph Apfalter, Petra Machherndl-Spandl, Sigrid Kerschner, Heidrun |
author_sort | Berning, Lucia |
collection | PubMed |
description | BACKGROUND: Respiratory tract infections are widespread and may cause significant morbidity and mortality in immunosuppressed populations such as oncological patients. OBJECTIVES: The RealAccurate Respiratory RT PCR Kit covering 14 respiratory viruses was compared to the RespiFinder Smart22, a broad-spectrum multiplex ligation-dependent probe amplification (MLPA) test, targeting 22 viral and bacterial respiratory pathogens. STUDY DESIGN: After verification of its analytical performance, the clinical performance of the RespiFinder Smart22 was evaluated by re-analysis of 96 respiratory samples from oncological patients. Additionally, the time to result (TTR) of both methods was compared. RESULTS: The analytical performance of the RespiFinder Smart22 fulfilled all previously specified criteria. Concordant results in both assays were achieved in 74.0% of all clinical specimens and in 91.2% when only positive results were taken into account. The RespiFinder Smart22 yielded additional results in a total of 22 (22.9% of 96) samples due to higher test sensitivity and a broader, highly multiplexed spectrum of pathogens. The TTR of a typical routine test consisting of three samples were 206 and 356 min for the RealAccurate Respiratory RT PCR Kit and the RespiFinder Smart22, respectively. However, hands-on time was reduced by 59.0% applying the MLPA method. CONCLUSIONS: In our hands, the RespiFinder Smart22 showed excellent analytical performance while hands-on time was halved in comparison to the RT PCR method. Regarding the clinical evaluation, the MLPA method provided additional results in 22.9% (22/96) of specimens due to its comprehensive format, higher test sensitivity and the capability to detect 22 pathogens compared to 14 with the RealAccurate Respiratory RT PCR Kit. |
format | Online Article Text |
id | pubmed-7106480 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71064802020-03-31 Evaluation of a multiplex ligation-dependent probe amplification assay for the detection of respiratory pathogens in oncological patients Berning, Lucia Aberle, Stephan W. Simon, Benedikt Luger, Christoph Apfalter, Petra Machherndl-Spandl, Sigrid Kerschner, Heidrun J Clin Virol Article BACKGROUND: Respiratory tract infections are widespread and may cause significant morbidity and mortality in immunosuppressed populations such as oncological patients. OBJECTIVES: The RealAccurate Respiratory RT PCR Kit covering 14 respiratory viruses was compared to the RespiFinder Smart22, a broad-spectrum multiplex ligation-dependent probe amplification (MLPA) test, targeting 22 viral and bacterial respiratory pathogens. STUDY DESIGN: After verification of its analytical performance, the clinical performance of the RespiFinder Smart22 was evaluated by re-analysis of 96 respiratory samples from oncological patients. Additionally, the time to result (TTR) of both methods was compared. RESULTS: The analytical performance of the RespiFinder Smart22 fulfilled all previously specified criteria. Concordant results in both assays were achieved in 74.0% of all clinical specimens and in 91.2% when only positive results were taken into account. The RespiFinder Smart22 yielded additional results in a total of 22 (22.9% of 96) samples due to higher test sensitivity and a broader, highly multiplexed spectrum of pathogens. The TTR of a typical routine test consisting of three samples were 206 and 356 min for the RealAccurate Respiratory RT PCR Kit and the RespiFinder Smart22, respectively. However, hands-on time was reduced by 59.0% applying the MLPA method. CONCLUSIONS: In our hands, the RespiFinder Smart22 showed excellent analytical performance while hands-on time was halved in comparison to the RT PCR method. Regarding the clinical evaluation, the MLPA method provided additional results in 22.9% (22/96) of specimens due to its comprehensive format, higher test sensitivity and the capability to detect 22 pathogens compared to 14 with the RealAccurate Respiratory RT PCR Kit. Elsevier B.V. 2014-06 2014-03-06 /pmc/articles/PMC7106480/ /pubmed/24684925 http://dx.doi.org/10.1016/j.jcv.2014.02.010 Text en Copyright © 2014 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Berning, Lucia Aberle, Stephan W. Simon, Benedikt Luger, Christoph Apfalter, Petra Machherndl-Spandl, Sigrid Kerschner, Heidrun Evaluation of a multiplex ligation-dependent probe amplification assay for the detection of respiratory pathogens in oncological patients |
title | Evaluation of a multiplex ligation-dependent probe amplification assay for the detection of respiratory pathogens in oncological patients |
title_full | Evaluation of a multiplex ligation-dependent probe amplification assay for the detection of respiratory pathogens in oncological patients |
title_fullStr | Evaluation of a multiplex ligation-dependent probe amplification assay for the detection of respiratory pathogens in oncological patients |
title_full_unstemmed | Evaluation of a multiplex ligation-dependent probe amplification assay for the detection of respiratory pathogens in oncological patients |
title_short | Evaluation of a multiplex ligation-dependent probe amplification assay for the detection of respiratory pathogens in oncological patients |
title_sort | evaluation of a multiplex ligation-dependent probe amplification assay for the detection of respiratory pathogens in oncological patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106480/ https://www.ncbi.nlm.nih.gov/pubmed/24684925 http://dx.doi.org/10.1016/j.jcv.2014.02.010 |
work_keys_str_mv | AT berninglucia evaluationofamultiplexligationdependentprobeamplificationassayforthedetectionofrespiratorypathogensinoncologicalpatients AT aberlestephanw evaluationofamultiplexligationdependentprobeamplificationassayforthedetectionofrespiratorypathogensinoncologicalpatients AT simonbenedikt evaluationofamultiplexligationdependentprobeamplificationassayforthedetectionofrespiratorypathogensinoncologicalpatients AT lugerchristoph evaluationofamultiplexligationdependentprobeamplificationassayforthedetectionofrespiratorypathogensinoncologicalpatients AT apfalterpetra evaluationofamultiplexligationdependentprobeamplificationassayforthedetectionofrespiratorypathogensinoncologicalpatients AT machherndlspandlsigrid evaluationofamultiplexligationdependentprobeamplificationassayforthedetectionofrespiratorypathogensinoncologicalpatients AT kerschnerheidrun evaluationofamultiplexligationdependentprobeamplificationassayforthedetectionofrespiratorypathogensinoncologicalpatients |